B2N Accelerates New Business with Medicloud

BTuen, an AI and big data specialized company (CEO Taeil An), announced on the 29th that it will actively promote Medicloud and the pet business, which it invested in last year to pursue new business ventures.

BTuen is developing a pet urine diagnostic kit based on Medicloud's genetic analysis technology through Sus Korea. A company official stated, "It is planned to include the largest number of test items in Korea, and we are also preparing for US FDA and European CE certifications," adding, "We have secured channels for sales not only domestically but also in the US and overseas, and will start full-scale sales in May."

Previously, BTuen invested in Medicloud with the purpose of promoting pet DNA testing and insurance services, including a pet genetic database service. Medicloud, led by Dr. Hyungki Lee from Seoul National University, is a customized medical genome database service company. Although it recorded a net loss last year, it is expected that sales will significantly increase this year as product research and development are completed and the business is actively promoted.

Additionally, Medicloud received an A grade in the technology special listing preliminary evaluation in December last year, and with the full commencement of procedures for this year's IPO, it has begun preparations for listing within the year.